First-in-human results prompt a biomarker-defined approach for CID-078.
ApexOnco Front Page
Recent articles
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
The group wants to improve on its own Welireg in a new phase 3 trial.
After a delay, the Alpha-3 study faces an April futility analysis.
Early data are coming with the KRAS G12D degrader ARV-806.
A first-in-human trial of PRT12396 starts next month.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
